Terms: = Leukemia AND SF3B1, ENSG00000115524, 23451, O75533, SF3b155, SAP155, PRPF10, PRP10 AND Clinical Outcome
16 results:
1. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Ozga M; Nicolet D; Mrózek K; Yilmaz AS; Kohlschmidt J; Larkin KT; Blachly JS; Oakes CC; Buss J; Walker CJ; Orwick S; Jurinovic V; Rothenberg-Thurley M; Dufour A; Schneider S; Sauerland MC; Görlich D; Krug U; Berdel WE; Woermann BJ; Hiddemann W; Braess J; Subklewe M; Spiekermann K; Carroll AJ; Blum WG; Powell BL; Kolitz JE; Moore JO; Mayer RJ; Larson RA; Uy GL; Stock W; Metzeler KH; Grimes HL; Byrd JC; Salomonis N; Herold T; Mims AS; Eisfeld AK
Leukemia; 2024 Jan; 38(1):45-57. PubMed ID: 38017103
[TBL] [Abstract] [Full Text] [Related]
2. The clinical phenotype of germline RUNX1 mutations in relation to the accompanying somatic variants and RUNX1 isoform expression.
Cabrerizo Granados D; Barbosa I; Baliakas P; Hellström-Lindberg E; Lundin V
Genes Chromosomes Cancer; 2023 Nov; 62(11):672-677. PubMed ID: 37303296
[TBL] [Abstract] [Full Text] [Related]
3. Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes.
Konishi T; Sadato D; Toya T; Hirama C; Kishida Y; Nagata A; Yamada Y; Shingai N; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Okuyama Y; Harada H; Ohashi K; Harada Y; Doki N
Sci Rep; 2023 Feb; 13(1):2641. PubMed ID: 36788335
[TBL] [Abstract] [Full Text] [Related]
4. sf3b1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis.
Huber S; Haferlach T; Meggendorfer M; Hutter S; Hoermann G; Baer C; Kern W; Haferlach C
Leukemia; 2022 Dec; 36(12):2894-2902. PubMed ID: 36261576
[TBL] [Abstract] [Full Text] [Related]
5. Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation.
Bracher S; Fuhrmann I; Jeromin S; Nadarajah N; Kern W; Haferlach T; Haferlach C; Stengel A
Mol Biol Rep; 2022 Dec; 49(12):12247-12252. PubMed ID: 36169893
[TBL] [Abstract] [Full Text] [Related]
6. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification.
van der Werf I; Wojtuszkiewicz A; Meggendorfer M; Hutter S; Baer C; Heymans M; Valk PJM; Kern W; Haferlach C; Janssen JJWM; Ossenkoppele GJ; Cloos J; Haferlach T
Blood Adv; 2021 Sep; 5(17):3254-3265. PubMed ID: 34448812
[TBL] [Abstract] [Full Text] [Related]
7. The protein landscape of chronic lymphocytic leukemia.
Meier-Abt F; Lu J; Cannizzaro E; Pohly MF; Kummer S; Pfammatter S; Kunz L; Collins BC; Nadeu F; Lee KS; Xue P; Gwerder M; Roiss M; Hüllein J; Scheinost S; Dietrich S; Campo E; Huber W; Aebersold R; Zenz T
Blood; 2021 Dec; 138(24):2514-2525. PubMed ID: 34189564
[TBL] [Abstract] [Full Text] [Related]
8. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
[TBL] [Abstract] [Full Text] [Related]
9. MYC copy number and mRNA expression in chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chornobyl NPP accident.
Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
Exp Oncol; 2020 Mar; 42(1):60-65. PubMed ID: 32231192
[TBL] [Abstract] [Full Text] [Related]
10. Negative impact on clinical outcome of the mutational co-occurrence of sf3b1 and DNMT3A in refractory anemia with ring sideroblasts (RARS).
Martín I; Such E; Navarro B; Vicente A; López-Pavía M; Ibáñez M; Tormo M; Villamón E; Gómez-Seguí I; Luna I; Oltra S; Pedrola L; Sanz MA; Cervera J; Sanz G
Leuk Lymphoma; 2017 Jul; 58(7):1686-1693. PubMed ID: 27771989
[TBL] [Abstract] [Full Text] [Related]
11. Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts clinical outcome in Chronic Lymphocytic leukemia.
Janovska P; Poppova L; Plevova K; Plesingerova H; Behal M; Kaucka M; Ovesna P; Hlozkova M; Borsky M; Stehlikova O; Brychtova Y; Doubek M; Machalova M; Baskar S; Kozubik A; Pospisilova S; Pavlova S; Bryja V
Clin Cancer Res; 2016 Jan; 22(2):459-69. PubMed ID: 26240275
[TBL] [Abstract] [Full Text] [Related]
12. Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.
Sciumè M; Vincenti D; Reda G; Orofino N; Cassin R; Giannarelli D; Gaidano G; Rossi D; Cortelezzi A
Am J Hematol; 2015 Nov; 90(11):970-4. PubMed ID: 26201283
[TBL] [Abstract] [Full Text] [Related]
13. Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.
Shahjahani M; Mohammadiasl J; Noroozi F; Seghatoleslami M; Shahrabi S; Saba F; Saki N
Cell Oncol (Dordr); 2015 Apr; 38(2):93-109. PubMed ID: 25563586
[TBL] [Abstract] [Full Text] [Related]
14. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model.
Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Royo C; Navarro A; Pinyol M; Rozman M; Pereira A; Villamor N; Aymerich M; López C; Carrió A; Montserrat E
Haematologica; 2014 Oct; 99(10):1599-604. PubMed ID: 24972773
[TBL] [Abstract] [Full Text] [Related]
15. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: different genetic mechanisms but equivalent poorer clinical outcome.
Puiggros A; Venturas M; Salido M; Blanco G; Fernandez-Rodriguez C; Collado R; Valiente A; Ruiz-Xivillé N; Carrió A; Ortuño FJ; Luño E; Calasanz MJ; Ardanaz MT; Piñán MÁ; Talavera E; González MT; Ortega M; Marugán I; Ferrer A; Gimeno E; Bellosillo B; Delgado J; Hernández JÁ; Hernández-Rivas JM; Espinet B; ;
Genes Chromosomes Cancer; 2014 Sep; 53(9):788-97. PubMed ID: 24915757
[TBL] [Abstract] [Full Text] [Related]
16. clinical significance of sf3b1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract] [Full Text] [Related]
